Table 1.

Table of included studies and characteristics. I, intervention; C, comparator; PCI, prophylactic cranial irradiation; HR, hazard ratio; mPFS, median progression-free survival; mOS, median overall survival; EP, etoposide platinum; Y, yes.

First Author	Year	Title	Type of Publication	Type of Study	Total No. of Patients		Intervention	Comparator	Main	PCI	HR for PFS	mPFS (Treatment)	mPFS (Control)	HR for OS	mOS (Treatment)	mOS (Control)
					I	C
Wang	2022	CAPSTONE-1 [26]	Publication	Phase III RCT	230	232	Adebrelimab 20 mg/kg (Cycle 1–6) EP q3w × 4–6 Carbo	EP q3w × 4–6	Y	Y	0.67	5.8	5.6	0.72	15.3	12.8
Cheng	2022	ASTRUM-005 [27]	Abstract	Phase III RCT	389	196	Serplulimab 4.5 mg/kg × 4 EP q3w × 4 Carbo	EP q3w × 4	Y	?	0.48	5.7	4.3	0.63	15.4	10.9
Reck	2013	CA184-041 [28]	Publication	Phase II RCT	43	45	Concurrent Ipilimumab 10 mg/kg (Cycle 1–4) Carbo/Pacli × 6	Carbo/Pacli	Y	?	0.93	3.89	5.19	0.95	9.13	9.92
Reck	2013	CA184-041 [28]	Publication	Phase II RCT	42	45	Phased Ipilimumab 10 mg/kg (Cycle 3–6) Carbo/Pacli × 6	Carbo/Pacli	Y	?	0.93	5.22	5.19	0.75	12.94	9.92
Reck	2016	CA 184–156 [13]	Publication	Phase III RCT	566	566	Phased Ipilimumab 10 mg/kg (Cycle 3–6) EP q3w × 4 Cis or Carbo	EP q3w × 6	Y	Y	0.85	4.6	4.4	0.81	11	10.9
Horn	2018	IMpower133 [14]	Publication	Phase III RCT	201	202	Atezolizumab 1200 mg q3w EP q3w × 4 (carbo)	EP q3w × 4	Y	Y	0.77	5.2	4.3	0.70	12.3	10.3
Paz-Ares	2019	CASPIAN [15]	Publication	Phase III RCT	268	269	Durvalumab 1500 mg q3w EP q3w × 4 Cis or carbo	EP × 6 cycles	Y	Y	0.80	5.1	5.4	0.73	13.0	10.3
Goldman	2021	CASPIAN [29]	Publication	Phase III RCT	268	269	Durvalumab 1500 mg q3w Tremelimumab 75 mg q3w EP q3w	EP × 6 cycles	Y	Y	0.84	4.9	5.4	0.82	10.4	10.5
Rudin	2020	KEYNOTE-604 [30]	Publication	Phase III RCT	228	225	Pembro EP q3w Cis or Carbo	EP q3w × 4 cycles	Y	Y	0.73	4.8	4.3	0.80	10.8	9.7
Leal	2020	EA5161 [31]	Abstract	Phase II RCT	80	80	Nivolumab 360 mg q3w EP q3w × 4 Cis or carbo	EP q3w × 4 cycles	Y	?	0.65	5.5	4.6	0.67	11.3